Niowave, Inc. and Ratio Therapeutics Sign Supply Agreement for Actinium-225 to Advance Targeted Alpha Therapies
Summary
Niowave and Ratio Therapeutics have signed a supply agreement for cGMP Actinium-225. The deal gives Ratio a more reliable source of the isotope for ongoing clinical work and future radiotherapeutic development. Niowave strengthens its position as a supplier for radiopharmaceutical programs that need scalable Actinium-225 access. The agreement also reflects rising demand for targeted alpha therapies and the need to secure domestic isotope supply for commercialization.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected